IOSPBasic Materials · Specialty ChemicalsThe 3 Wall Street analysts covering Innospec, Inc. hold a median 12-month price target of $100 — +7.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 10 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Innospec, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (90): Analysts have, on balance, been raising their forecasts.
Accruals (36): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (34): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IOSP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2025 | Freedom Capital Markets | Initiates | Buy | $93 |
| 21 Apr 2025 | Seaport Global | Upgrade | Buy | — |
| 30 Mar 2022 | Seaport Global | Initiates | Neutral | — |
| 4 Sept 2019 | CL King | Initiates | Buy | — |
| 12 Apr 2019 | Keybanc | Downgrade | Sector Weight | — |
| 12 Apr 2019 | KeyBanc | Downgrade | Sector Weight | — |
| 16 Nov 2018 | Keybanc | Maintains | Overweight | — |
| 16 Nov 2018 | KeyBanc | Maintains | Overweight | — |
| 13 July 2018 | Keybanc | Maintains | Overweight | — |
| 13 July 2018 | KeyBanc | Maintains | Overweight | — |
| 24 Apr 2018 | Johnson Rice | Upgrade | Buy | — |
| 14 Nov 2017 | Johnson Rice | Upgrade | Accumulate | — |
| 9 Nov 2017 | Keybanc | Maintains | Overweight | — |
| 9 Nov 2017 | KeyBanc | Maintains | Overweight | — |
| 9 Nov 2017 | Monness Crespi Hardt | Downgrade | Neutral | — |
| 9 Nov 2017 | Monness, Crespi, Hardt | Downgrade | Neutral | — |
| 22 Aug 2017 | Monness Crespi Hardt | Upgrade | Buy | — |
| 22 Aug 2017 | Monness, Crespi, Hardt | Upgrade | Buy | — |
| 19 Dec 2016 | Monness Crespi Hardt | Downgrade | Neutral | — |
| 19 Dec 2016 | Monness, Crespi, Hardt | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IOSP appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Innospec, Inc. returned +14.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 39% of US stocks
Cheaper than 65% of US stocks
Cheaper than 51% of US stocks
Cheaper than 34% of US stocks
Higher than 57% of US stocks
Higher than 66% of US stocks
Higher than 31% of US stocks
Higher than 61% of US stocks
Higher than 64% of US stocks
Higher than 61% of US stocks
Higher than 77% of US stocks
Higher than 44% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Innospec, Inc. has a market value of $2.3B and an enterprise value of $2.1B.
Revenue in the twelve months to 30 June 2026: $1.8B. The latest quarter grew 11.8% year on year.
Net income over the same four quarters: $122.3M, a 6.6% net margin.
Diluted earnings per share, trailing twelve months: $4.90.
Trailing P/E: 19.0×; forward P/E: 15.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.97%, paying out 37% of earnings.
Innospec, Inc. employs 2,450 people — $752K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Innospec, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Innospec (IOSP) reported earnings 30 days ago, and its stock has risen 2% since that report. The article examines what may come next for the company's shares.
Why it matters — A Innospec watcher would track its post-earnings stock movement and outlook after the recent quarterly report.
Zacks Research reports that the Chemicals Diversified sector is expected to benefit from healthy demand across major end-use markets and the end of destocking activities. The article names APD, DD, AVNT and IOSP as companies positioned to gain from strategic actions and demand recovery.
Why it matters — The report indicates that Innospec is among the diversified chemical stocks expected to benefit from stabilizing end-market demand and the conclusion of destocking.
Innospec's topline grew as expected in Q2 2026, with revenue up 12% and beating estimates by $34.17 million, led by the oilfield segment's DRA adoption and re-entry into the Mexico market. However, the Performance Chemicals segment continues to see volume declines, raising concerns about over-investment in capacity.
Why it matters — Investors should note that while topline growth is on track from oilfield and market expansion, ongoing weakness in the Performance Chemicals segment may weigh on overall returns for IOSP.
Innospec's second-quarter earnings surpassed estimates, driven by revenue growth across all three of its business segments. The company also maintains a debt-free balance sheet, which positions it for further investment.
Why it matters — The broad-based revenue growth and debt-free position indicate sound operational health and financial flexibility for future investment.
The article compares Innospec's year-to-date stock performance against its basic materials peers, including Ingevity.
Why it matters — Investors tracking IOSP can gauge how its relative performance stacks up within the basic materials sector.
The 3 Wall Street analysts covering Innospec, Inc. have a median 12-month price target of $100, with estimates ranging from $93 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Innospec, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Innospec, Inc. 90 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Sept 2026, Innospec, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (90 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +7.3% from the last close, and Ticker Nerd's factor model ranks Innospec, Inc. 90 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Innospec, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IOSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $93 to $110 over the next 12 months.
Innospec, Inc. returned +14.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Innospec Inc. is an international specialty chemicals company that develops, manufactures, blends, markets, and supplies performance-critical chemical solutions for industrial customers.
The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Innospec (IOSP) Up 2% Since Last Earnings Report: Can It Continue?". Innospec (IOSP) reported earnings 30 days ago, and its stock has risen 2% since that report. The article examines what may come next for the company's shares.
Innospec Inc. is an international specialty chemicals company that develops, manufactures, blends, markets, and supplies performance-critical chemical solutions for industrial customers. Innospec Inc. operates through three main business segments: Fuel Specialties, Performance Chemicals, and Oilfield Services. Its products include fuel additives that support engine performance and fuel efficiency, surfactants and specialty ingredients used in personal care and home care formulations, and chemicals for drilling, completion, and production operations in the oil and gas industry. The company also serves markets such as agrochemicals, construction, mining, polymers, and waxes, reflecting a broad industrial footprint. Innospec Inc. focuses on formulated, application-specific products rather than commodity chemicals, making it an important supplier across multiple end markets worldwide.
CEO Mr. Patrick S. Williams · 2,450 employees · United States · https://innospec.com
